Tag:

weight loss

Health

Retatrutide: Lilly’s Diabetes Drug Shows Significant Weight Loss & Blood Sugar Control

by Chief Editor
written by Chief Editor

Lilly’s Retatrutide: A New Era in Diabetes and Weight Management?

Eli Lilly’s investigational drug, retatrutide, is generating significant buzz after demonstrating impressive results in a late-stage trial for Type 2 diabetes. The findings, released today, suggest a potential breakthrough in managing both blood sugar and weight – a historically challenging combination for individuals with the condition.

Unprecedented Weight Loss in Diabetes Patients

Traditionally, weight loss has been more difficult to achieve for people with Type 2 diabetes compared to those without the condition. Retatrutide appears to be changing that narrative. Participants on the highest dose (12mg) of retatrutide experienced an average weight loss of 16.8%, equivalent to approximately 36.6 pounds, over 40 weeks. Even when accounting for all participants, including those who stopped treatment, weight loss remained substantial at 15.3%.

What’s particularly encouraging is that weight loss didn’t appear to plateau during the study period, suggesting continued benefits with longer-term use. This contrasts with some existing weight loss medications where individuals may experience an initial rapid loss followed by stabilization.

Significant Improvements in Blood Sugar Control

Beyond weight loss, retatrutide similarly delivered substantial improvements in glycemic control. Patients taking retatrutide saw an average reduction of 1.7% to 2.0% in HbA1C levels – a key measure of blood sugar – compared to a 0.8% reduction in the placebo group. These results are comparable to those seen with Lilly’s already popular diabetes drug, Mounjaro.

How Does Retatrutide Work?

Retatrutide is a first-in-class triple hormone receptor agonist, meaning it targets three key hormones: GIP, GLP-1 and glucagon. By activating these receptors, the drug appears to enhance insulin secretion, suppress glucagon secretion, and slow gastric emptying, leading to both improved blood sugar control and reduced appetite.

The Future of Obesity and Cardiometabolic Health

Lilly is positioning retatrutide as a potential cornerstone of its cardiometabolic health portfolio, alongside Zepbound (its blockbuster weight loss injection) and orforglipron (an upcoming oral medication). The success of retatrutide in the Type 2 diabetes trial strengthens the company’s bet on triple agonist therapies as a next-generation approach to tackling obesity and related metabolic disorders.

The implications extend beyond diabetes. Given the strong link between obesity and numerous health conditions – including heart disease, stroke, and certain cancers – effective weight management strategies are increasingly crucial for public health. Retatrutide’s potential to deliver significant and sustained weight loss could have a far-reaching impact.

What’s Next for Retatrutide?

Lilly is currently conducting additional Phase 3 clinical trials to evaluate retatrutide’s efficacy and safety in individuals with obesity or overweight and at least one weight-related medical problem. The results of these trials will be critical in determining the drug’s potential for broader approval and use.

Frequently Asked Questions

What is HbA1C?

HbA1C is a measure of your average blood sugar levels over the past 2-3 months.

What are GIP, GLP-1, and glucagon?

These are hormones that play key roles in regulating blood sugar, appetite, and metabolism.

Is retatrutide available now?

No, retatrutide is still an investigational drug and is not yet available for prescription. It is currently in clinical trials.

Pro Tip: Maintaining a healthy lifestyle, including a balanced diet and regular exercise, remains essential even with the use of medications like retatrutide.

Do you have questions about retatrutide or other diabetes treatments? Share your thoughts in the comments below!

Explore more articles on diabetes management and weight loss strategies.

0 comments
0 FacebookTwitterPinterestEmail
Health

What really happens after coming off Ozempic and other weight-loss drugs?

by Chief Editor
written by Chief Editor

The Ozempic Effect: What Happens When the Shots Stop?

Millions have turned to GLP-1 medications like Ozempic, Wegovy, and Zepbound for weight loss, but a crucial question remains: what happens when patients discontinue use? Initial concerns centered around significant weight regain, mirroring the results seen in tightly controlled clinical trials. But, emerging real-world data paints a more nuanced picture.

Beyond the Clinical Trial: Real-World Outcomes

A recent study from the Cleveland Clinic, published in the journal Diabetes, Obesity and Metabolism, analyzed data from nearly 8,000 adults in Ohio and Florida who used semaglutide or tirzepatide for three to twelve months before stopping. Unlike the rigid environments of clinical trials, this study reflected how patients navigate treatment in everyday life – often switching between medications.

The findings offer a hopeful perspective. Patients did not experience substantial weight regain in the year following discontinuation of GLP-1 medication. For those specifically treated for obesity, the average weight loss prior to stopping was 8.4%, and they only regained 0.5% on average one year later.

Why the Difference? The Role of Continued Care

Dr. Hamlet Gasoyan, lead study author, suggests the discrepancy between clinical trial results and real-world outcomes lies in continued engagement with the healthcare system. “Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials,” he stated.

This highlights a critical point: successful weight management isn’t solely about the medication itself, but about ongoing support and alternative options when a patient stops the initial treatment.

Transitioning and Adapting: What Patients Are Doing

The Cleveland Clinic study revealed that approximately 27% of patients transitioned to different medications, including older-generation obesity drugs. Another 20% eventually restarted their original medication after resolving issues like insurance coverage or side effects. 14% engaged in intensive lifestyle modification programs, working with dietitians and exercise specialists.

These findings suggest that patients are actively seeking and utilizing alternative strategies to maintain their weight loss journey, mitigating the risk of significant regain.

Limitations and Future Research

Researchers acknowledge the study’s limitations, noting that the data was drawn from a single integrated health system in Ohio and Florida. Patient characteristics and healthcare delivery models vary across the U.S., potentially impacting the generalizability of the findings.

Future research will focus on comparing the effectiveness of different treatment options for patients discontinuing semaglutide or tirzepatide, aiming to provide clinicians and patients with informed decision-making tools.

FAQ: GLP-1 Discontinuation

Q: Will I definitely regain weight if I stop Ozempic or Wegovy?
A: Not necessarily. This study suggests that many patients do not regain significant weight, particularly if they transition to another treatment or lifestyle program.

Q: What are the alternatives to GLP-1 medications?
A: Alternatives include older-generation obesity drugs, intensive lifestyle modification programs (diet and exercise), and potentially surgery.

Q: Is this study applicable to everyone?
A: The study was conducted within a specific healthcare system. Results may vary depending on individual circumstances and access to care.

Q: What should I do if I’m considering stopping a GLP-1 medication?
A: Discuss your options with your healthcare provider to develop a plan for continued weight management.

Did you know? Patients who remain engaged with the healthcare system – through alternative prescriptions or lifestyle support – are more likely to maintain their weight loss after stopping GLP-1 medications.

Explore more health stories on Fox News Digital.

Sign up for our health newsletter to stay informed about the latest medical breakthroughs and wellness tips: Click here to subscribe.

0 comments
0 FacebookTwitterPinterestEmail
Health

Boston wants to limit GLP-1 drug coverage amid rising costs

by Chief Editor
written by Chief Editor

Boston Faces Healthcare Cost Crisis: GLP-1 Drugs Drive Up Premiums

Boston is bracing for a significant spike in health insurance costs, with premiums potentially increasing by nearly 23% in the upcoming fiscal year. The primary driver behind this surge? The growing utilize of GLP-1 medications, a class of drugs initially designed for diabetes treatment but increasingly popular for weight loss.

The Rising Cost of GLP-1s

City officials are grappling with the financial implications of these medications, like Ozempic and Wegovy. Currently, GLP-1 medications account for roughly 15% of the city’s projected overall healthcare cost increase. Spending on these drugs is estimated at $31.6 million for the current fiscal year and is projected to climb to $47.4 million next year. Despite only approximately 7.7% of non-Medicare plan members utilizing GLP-1s for weight loss, this represents nearly 15% of the projected cost increase.

Impact on City Employees and Retirees

The proposed premium increases will directly impact the 55,000 members of the city’s health insurance system, including employees, families and retirees. For those in one Blue Cross Blue Shield family plan, monthly premiums could jump from $655 to $803, adding $1,773 to their annual expenses.

A Battle with Unions Over Cost Control

To mitigate these rising costs, the Wu administration proposed “utilization management” – requiring prior authorization from insurance providers before prescribing certain medications. This change was projected to save the city between $8 million and $9 million annually. However, the Public Employee Committee (PEC), representing unionized city employees and retirees, voted against the proposal earlier this month.

Larry Calderone, president of the Boston Police Patrolmen’s Association, expressed openness to negotiations, emphasizing the need to balance cost containment with access to necessary medications. Elissa Cadillic, cochair of the PEC, voiced concerns that the city’s proposal could extend to all non-specialty medications, not just GLP-1s, and questioned the projected savings.

Following a National Trend

Boston isn’t alone in facing this challenge. Several states and cities across the country are grappling with the escalating costs of GLP-1 medications. Massachusetts’ Group Insurance Commission recently eliminated GLP-1 coverage for state employees due to budget constraints. Similar cuts have occurred in New Hampshire, North Carolina, and New York City.

More than 40,000 customers of Massachusetts’ two biggest insurers, Blue Cross and Point32Health, have lost coverage of GLP-1s for obesity this year.

The City’s Financial Position

Ashley Groffenberger, Boston’s Chief Financial Officer, emphasized the city’s limited financial flexibility. She stated that projected revenue increases of only 1.5 to 2.5% for the next fiscal year leave fewer resources to absorb the rising healthcare costs. She is now requesting the City Council’s support in urging the PEC to reconsider its vote before the complete of the week.

FAQ

Q: What are GLP-1 medications?
A: GLP-1 medications are a class of drugs originally used to treat type 2 diabetes. They have become popular for weight loss due to their ability to suppress appetite and improve blood sugar control.

Q: Why are GLP-1 medications so expensive?
A: The high cost is due to a combination of factors, including research and development expenses, manufacturing costs, and high demand.

Q: What is “utilization management”?
A: Utilization management refers to strategies used by insurance companies to control healthcare costs, such as requiring prior authorization for certain medications or procedures.

Q: What happens if the PEC doesn’t reconsider its vote?
A: The city may have to consider other options, including joining the Massachusetts’ Group Insurance Commission, which has already eliminated GLP-1 coverage for state employees.

Did you know? The city of Boston included $483 million for all health-related benefits for employees and retirees in its current budget.

Pro Tip: Stay informed about your health insurance coverage and discuss medication costs with your doctor to explore affordable alternatives.

Have questions about Boston’s healthcare costs? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Is it time to go bananas for bananas? 3 health benefits

by Chief Editor
written by Chief Editor

The Future of Fruit: Beyond Apples and Oranges

For generations, apples and oranges have reigned supreme as America’s favorite fruits. But a shift is underway. While these classics aren’t disappearing, emerging trends suggest a growing appetite for variety, sustainability, and fruits offering unique nutritional benefits. This isn’t just about taste. it’s about adapting to changing climates, prioritizing health, and rediscovering forgotten treasures.

The Orange Crisis and the Rise of Alternatives

Recent news highlights a concerning trend: Florida’s orange crop has hit a 95-year low. This isn’t simply a regional issue; it impacts supply chains and prices nationwide. As traditional citrus production faces challenges from climate change and disease, consumers are increasingly open to exploring alternatives. Bananas, already a popular choice, are solidifying their position as a staple, offering affordability and versatility.

Rediscovering America’s Forgotten Fruit: The Pawpaw

One fascinating development is the resurgence of the pawpaw, a native American fruit once widely consumed by Indigenous populations. Often described as a blend between a banana, mango, and custard apple, the pawpaw is gaining traction among foodies and sustainability-minded consumers. Its ability to thrive in local ecosystems, requiring minimal intervention, makes it an attractive option in a world increasingly focused on reducing food miles.

The Power of Potassium and Beyond: Nutritional Trends

Consumer awareness of nutritional benefits is driving fruit choices. Bananas, renowned for their potassium content – roughly 375 milligrams per medium fruit – are benefiting from this trend. Potassium is an essential electrolyte, supporting muscle function, heart health, and hydration. However, the focus isn’t solely on potassium. There’s a growing interest in fruits rich in fiber, vitamins C and B6, and other essential nutrients.

Carb Consciousness: The Ripening Debate

Understanding carbohydrate composition is becoming increasingly important. The carb content in bananas shifts as they ripen, transitioning from resistant starch (in greener bananas) to simpler sugars. This knowledge empowers consumers to choose bananas based on their individual dietary needs and preferences. Those managing blood sugar may opt for less ripe varieties, while others might prefer the sweetness of a fully ripened banana.

Fiber’s Role in Gut Health and Weight Management

The importance of dietary fiber is gaining widespread recognition. Bananas, with their combination of resistant starch and pectin, contribute to digestive health. Fiber promotes satiety, aids in regulating blood sugar levels, and supports a healthy gut microbiome. This makes bananas a potentially valuable component of weight management strategies.

Plantains: A Starchy Cousin Gains Popularity

Related to bananas, plantains are experiencing a surge in interest. Larger and starchier than their sweeter cousins, plantains are typically cooked before consumption. Their higher fiber content and unique flavor profile appeal to those seeking diverse culinary experiences and nutritional benefits.

The Future of Fruit Consumption: Sustainability and Local Sourcing

Looking ahead, sustainability will be a key driver of fruit consumption. Consumers are increasingly seeking locally sourced options, reducing their carbon footprint and supporting regional agriculture. The pawpaw’s resurgence exemplifies this trend, highlighting the potential of rediscovering and cultivating native fruit varieties. Expect to notice more emphasis on fruits that require less water, fewer pesticides, and can thrive in changing climates.

FAQ

Are bananas good for weight loss? Bananas can be part of a weight-loss plan due to their fiber content, which promotes fullness. However, moderation is key.

What is the difference between a banana and a plantain? Plantains are starchier and less sweet than bananas and are typically cooked before eating.

How much potassium is in a banana? A medium banana contains approximately 375 milligrams of potassium.

Are green bananas healthier than ripe bananas? Green bananas have more resistant starch, which can be beneficial for blood sugar control and gut health. Ripe bananas are easier to digest and sweeter.

What are the benefits of pawpaws? Pawpaws are a good source of vitamins and minerals and are native to North America, making them a sustainable choice.

Do bananas have a lot of sugar? A medium banana contains about 18.2 grams of total sugars.

Can bananas interact with medications? Bananas, due to their high potassium content, may interact with certain blood pressure medications. Consult your healthcare provider if you have concerns.

Pro Tip: Pair your banana with a source of protein or healthy fat, like a handful of nuts or a spoonful of almond butter, to support stabilize blood sugar levels and preserve you feeling fuller for longer.

Did you know? Bananas are technically berries!

Explore more about healthy eating and nutrition on ForHers.com.

0 comments
0 FacebookTwitterPinterestEmail
Health

Serena Williams Embraces ‘Not Perfect’ Body Amid Weight Loss

by Chief Editor
written by Chief Editor

Serena Williams and the Rise of GLP-1 Medications: A New Era of Body Image and Wellness?

Serena Williams’ recent openness about her 31-pound weight loss journey using GLP-1 medication has ignited a conversation about the evolving landscape of body image, wellness, and the use of pharmaceutical interventions for weight management. The tennis icon’s experience, shared alongside a striking swimsuit photo on Instagram, reflects a broader trend of celebrities and individuals embracing these medications, sparking both praise and criticism.

The GLP-1 Revolution: Beyond Diabetes

Originally developed to treat type 2 diabetes, GLP-1 (glucagon-like peptide-1) receptor agonists like Wegovy and Ozempic have gained significant traction as weight-loss tools. These medications work by mimicking the effects of the GLP-1 hormone, which regulates appetite and blood sugar levels. While effective, their increasing popularity has led to scrutiny regarding accessibility, potential side effects, and the societal pressures surrounding weight loss.

Williams’ Personal Journey: Postpartum Recovery and Beyond

Williams revealed she initially explored GLP-1 medication after struggling to lose weight following the birth of her daughter Olympia in 2017. She described a frustrating experience of intense effort – healthy eating and rigorous exercise – that failed to yield desired results. After giving birth to her second daughter, Adira, in 2023, she faced similar challenges and began using Ro in 2024, becoming a spokesperson for the company. “I feel great,” Williams told People, noting improvements in her energy levels and joint health. She emphasized that she never felt pressured to conform to a specific body image.

The Controversy: Celebrity Endorsements and Accessibility

The embrace of GLP-1 drugs by high-profile figures like Williams, Rebel Wilson, and Lizzo has drawn criticism, with some arguing that it normalizes the pursuit of quick fixes and potentially overshadows the importance of holistic health practices. Concerns also exist regarding the limited availability of these medications and their cost, raising questions about equity and access. The medications are intended for long-term use, and the long-term effects are still being studied.

Beyond Weight Loss: The Potential Health Benefits

While weight loss is the most visible outcome, GLP-1 medications have demonstrated potential benefits beyond aesthetics. Studies suggest they can improve cardiovascular health, reduce the risk of type 2 diabetes, and even have positive effects on certain neurological conditions. However, these benefits require further research and should be considered within a comprehensive healthcare plan.

The Future of Weight Management: A Multifaceted Approach

The rise of GLP-1 medications signals a shift in the approach to weight management. Experts predict a future where personalized medicine, combining pharmaceutical interventions with lifestyle modifications – diet, exercise, and mental wellness – will become the norm. Technology, such as wearable sensors and AI-powered coaching apps, will likely play an increasingly important role in monitoring progress and tailoring interventions to individual needs.

Frequently Asked Questions (FAQ)

  • What are GLP-1 medications? They are medications originally designed for type 2 diabetes that also promote weight loss by regulating appetite and blood sugar.
  • Are GLP-1 medications safe? They are generally considered safe when prescribed and monitored by a healthcare professional, but can have side effects.
  • Is this just a celebrity trend? While celebrity endorsements have brought attention to these medications, the underlying demand for effective weight management solutions is widespread.
  • Can I get GLP-1 medication? These medications require a prescription from a doctor.

Pro Tip: Before considering any weight-loss medication, consult with a healthcare professional to discuss your individual health needs and potential risks and benefits.

What are your thoughts on the use of GLP-1 medications? Share your perspective in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

FDA sends letter to Novo Nordisk over potential GLP-1 side effects

by Chief Editor
written by Chief Editor

FDA Scrutinizes Novo Nordisk: Reporting Lapses and Rising Safety Concerns with Ozempic & Wegovy

The FDA recently issued a warning letter to Novo Nordisk, the manufacturer of Ozempic and Wegovy, citing failures to adequately report potential adverse effects and deaths linked to the popular GLP-1 medications. This action underscores growing scrutiny surrounding these drugs as demand surges and potential risks come under closer examination.

The FDA’s Concerns: Delayed Reporting of Serious Events

The FDA’s warning, dated March 5, 2026, followed a post-marketing inspection of Novo Nordisk’s New Jersey facility in early 2025. The agency identified “serious violations” related to the timely reporting of adverse events. Specifically, the FDA cited three reported deaths among patients using semaglutide, the active ingredient in both Ozempic and Wegovy, including one case of suicide. The FDA clarified it has not determined if the drugs caused these events, but the reporting delays are the primary concern.

The Rise of Weight Loss Scams Exploiting GLP-1 Popularity

Alongside the FDA’s safety concerns, a parallel issue is emerging: a surge in scams capitalizing on the demand for GLP-1 medications. The Better Business Bureau (BBB) reports a significant increase in advertisements for supplements falsely claiming to deliver similar weight loss results. These scams often utilize deceptive tactics, including deepfake celebrity endorsements – such as a fabricated Oprah Winfrey advertisement – to mislead consumers.

Spotting a GLP-1 Scam: A Key Red Flag

The most significant indicator of a scam is the availability of treatment without a prescription. Legitimate GLP-1 prescriptions require a doctor’s oversight. The BBB advises consumers to thoroughly vet any company offering these medications without a prescription and to avoid sharing personal health or insurance information until legitimacy is confirmed.

Novo Nordisk’s Response and Future Outlook

Novo Nordisk acknowledged receiving the FDA’s warning letter and stated it has been “working diligently” to address the identified observations since February 2025. The company maintains it has taken significant steps to ensure compliance with reporting requirements and does not anticipate any disruption to production. Novo Nordisk welcomes further dialogue with the FDA to resolve the concerns.

What This Means for Patients

The FDA’s warning serves as a reminder of the importance of responsible medication use and the need for transparency in reporting adverse events. Patients considering or currently using Ozempic or Wegovy should discuss any concerns with their healthcare provider.

Frequently Asked Questions

What are GLP-1 medications?

GLP-1 medications, like Ozempic and Wegovy, are prescribed for both type 2 diabetes and weight loss.

What did the FDA warn Novo Nordisk about?

The FDA warned Novo Nordisk about failing to report potential side effects and deaths associated with Ozempic and Wegovy in a timely manner.

How can I avoid weight loss scams?

Be wary of any product advertised as a GLP-1 alternative that doesn’t require a prescription. Always consult with a healthcare professional.

Pro Tip: Always verify the legitimacy of any online pharmacy or healthcare provider before purchasing medications. Check for accreditation and read reviews.

Did you understand? The FDA’s warning letter is a public document available on the agency’s website. View the full warning letter here.

Updated: 3:04 PM PDT Mar 12, 2026

Editorial Standards ⓘ

0 comments
0 FacebookTwitterPinterestEmail
Health

Popular AI Chatbots Are Prescribing Dangerous Crash Diets to Teenagers Counter to Medical Guidelines

by Chief Editor
written by Chief Editor

AI Diet Plans: A Growing Threat to Teen Health

The promise of personalized nutrition delivered through artificial intelligence is alluring, especially for teenagers who may face barriers to accessing registered dietitians. However, a recent study published in Frontiers in Nutrition reveals a concerning trend: AI-generated meal plans for adolescents are often dangerously inadequate, potentially jeopardizing their growth and development.

The Calorie Deficit Problem

Researchers tested five leading AI models, tasking them with creating three-day weight-loss plans for 15-year-olds. The results were alarming. On average, the AI plans prescribed nearly 700 fewer calories per day than recommended by human dietitians – equivalent to skipping an entire meal. This isn’t a minor oversight; it’s a significant deficit during a critical period of growth.

Macronutrient Imbalance: A Recipe for Risk

The issue extends beyond calorie counting. AI models consistently skewed macronutrient ratios, favoring high protein and fat while drastically reducing carbohydrates. Human dietitians typically recommend carbohydrates make up 44-46% of daily energy intake, while the AI plans averaged only 32-36%. This reduction amounted to a loss of around 115 grams of necessary carbohydrates each day.

Dr. Ayşe Betül Bilen, assistant professor at Istanbul Atlas University and lead author of the study, explained that this imbalance is “particularly problematic for adolescents,” potentially impacting bone health, brain development and metabolic health.

Why Are AIs Getting It Wrong?

The problem stems from how AI models learn. They absorb information from the internet, including the pervasive and often harmful diet culture that promotes restrictive eating. AI systems prioritize generating plausible responses, but aren’t necessarily programmed to adhere to strict clinical nutrition guidelines. As Dr. Bilen notes, the AI plans often resemble popular, but often unhealthy, weight-loss approaches found online.

The Appeal of AI and the Risks of Accessibility

The increasing reliance on chatbots for health advice is understandable. Professional dietitians can be expensive and challenging to access. However, the study underscores the dangers of substituting expert guidance with algorithms that lack the nuanced understanding of adolescent nutritional needs. The long-term consequences of consistently following these unbalanced plans could include stunted growth, metabolic issues, and disordered eating behaviors.

The Need for Better Guardrails

The researchers emphasize the urgent need for developers to incorporate stronger safety measures into AI nutrition tools. Dr. Bilen suggests that AI systems should automatically prioritize evidence-based guidelines and encourage consultation with qualified health professionals. Simply put, AI should augment, not replace, human expertise.

Pro Tip:

Before starting any new diet, especially if you’re a teenager, consult with a registered dietitian or healthcare provider. They can create a personalized plan that meets your individual needs.

The Future of AI and Nutrition: What to Expect

The current findings highlight a critical juncture in the intersection of AI and healthcare. As AI becomes more integrated into our lives, several trends are likely to emerge:

  • Increased Regulation: Governments and regulatory bodies may start to establish standards and guidelines for AI-powered health tools, ensuring they meet minimum safety and efficacy requirements.
  • Hybrid Models: The most effective solutions will likely involve a combination of AI and human expertise. AI can assist with data analysis and personalization, while dietitians provide clinical oversight and individualized counseling.
  • Improved Training Data: Developers will need to curate more robust and reliable training datasets, filtering out biased or inaccurate information.
  • Focus on Education: Public awareness campaigns will be crucial to educate users about the limitations of AI and the importance of seeking professional guidance.

FAQ

Q: Are all AI diet plans dangerous?
A: This study focused on free versions of several AI tools. Paid services may offer more accurate advice, but it’s still crucial to verify the information with a professional.

Q: What are the signs of an unhealthy diet plan?
A: Look for plans that severely restrict calories, eliminate entire food groups, or promote rapid weight loss.

Q: Can AI be helpful for nutrition?
A: AI has the potential to assist with meal planning and tracking, but it should not be used as a substitute for professional advice.

Q: What should I do if I’m concerned about my diet?
A: Talk to your doctor or a registered dietitian. They can assess your individual needs and create a safe and effective plan.

Don’t let the convenience of AI compromise your health. Prioritize evidence-based nutrition and seek guidance from qualified professionals to ensure you’re fueling your body for optimal growth and well-being.

0 comments
0 FacebookTwitterPinterestEmail
Health

New ‘keto pill’ mimics popular diet without giving up carbs

by Chief Editor
written by Chief Editor

The Future of Weight Loss: Could a Pill Replace the Keto Diet?

For years, the ketogenic diet – a high-fat, low-carb regimen – has been a popular, albeit restrictive, path to weight loss. But what if you could reap the metabolic benefits of keto without sacrificing your favorite foods? Bloom Science believes they’ve found a way, and it comes in capsule form.

How BL-001 Aims to Mimic Keto Without the Restrictions

Bloom Science is developing BL-001, an experimental drug designed to replicate the metabolic effects of the ketogenic diet. The core idea, as explained by CEO Christopher Reyes, is to “translate some of the metabolic biology of the ketogenic diet into a therapy people may be able to take as an oral daily capsule.” Unlike the keto diet, which requires strict adherence to a specific macronutrient ratio, BL-001 aims to deliver results without dietary limitations.

The pill isn’t about restricting calories; it’s about manipulating metabolism. BL-001 is composed of live bacteria naturally found in the gut microbiome. Researchers hypothesize that specific bacterial strains can influence fat metabolism and ketogenesis – the process of the body burning fat for fuel.

Phase 1 Trial Results: Promising Early Signs

Early results from a Phase 1 clinical trial are encouraging. Overweight participants receiving the highest dose of BL-001 experienced a placebo-adjusted weight loss of 2.3% over 28 days, with some individuals losing up to 4.9%. Importantly, 80% of those who lost weight maintained their results two weeks after stopping the treatment. The trial also reported no serious adverse events.

Currently, Bloom Science is conducting Phase 1b trials, enrolling obese adults to assess the drug’s effects over a 12-week period.

Beyond Weight Loss: Potential Applications for Neurological Disorders

Whereas initially focused on obesity, Bloom Science’s research extends beyond weight management. The company is also exploring BL-001’s potential to treat Dravet syndrome, a rare and severe form of epilepsy. This highlights the broader therapeutic possibilities of targeting the gut-brain axis – the complex communication network between the gut microbiome and the brain.

BL-001 vs. GLP-1 Drugs: A New Contender?

The emergence of GLP-1 drugs like Ozempic and Zepbound has revolutionized weight loss treatment. Though, these medications require injections, and some patients experience gastrointestinal side effects. Bloom Science aims to offer an alternative for individuals who qualify for GLP-1s but prefer an oral medication with potentially fewer side effects.

It’s still too early to definitively compare BL-001 to GLP-1 drugs, but the potential for a convenient, oral therapy is significant.

Frequently Asked Questions

What is the gut microbiome?
It’s the collection of viruses, bacteria, fungi, and other microorganisms that live in your digestive tract and play a crucial role in your health.
What is ketogenesis?
It’s the metabolic process where the body burns fat for fuel instead of carbohydrates.
Is BL-001 currently available?
No, BL-001 is still in clinical development and is not yet available to the public.
What are live biotherapeutics?
These are therapies that use live microorganisms to treat or prevent disease.

Want to stay updated on the latest breakthroughs in microbiome research? Visit Bloom Science’s website to learn more and follow their progress.

0 comments
0 FacebookTwitterPinterestEmail
Health

Is Ozempic Safe to Take If You Don’t Have Diabetes?

by Chief Editor
written by Chief Editor

The Ozempic Effect: How GLP-1s Are Reshaping Weight Management and What’s Next

The buzz around medications like Ozempic has exploded, moving from a quietly prescribed diabetes drug to a mainstream topic of conversation. But the story doesn’t end with a catchy jingle. We’re witnessing a potential paradigm shift in how we approach weight management, and understanding the nuances is crucial.

Beyond Diabetes: The Rise of GLP-1s for Weight Loss

Ozempic falls into a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1s). Originally designed to aid manage type 2 diabetes by improving insulin release and lowering blood glucose, GLP-1s also promote weight loss by reducing appetite and slowing digestion. Approximately 40 million people in the U.S. Have diabetes, and these medications offer a latest approach to managing the condition while potentially mitigating weight gain associated with other treatments.

While Ozempic isn’t FDA-approved for weight loss specifically, its off-label use has gained traction, with some studies showing significant weight loss in individuals without diabetes. One study evaluating almost 2,000 adults with a BMI of 30 or greater found an average weight loss of 14.9% from baseline with semaglutide, compared to 2.4% in the placebo group. Though, it’s important to note this study was funded by Novo Nordisk, the manufacturer of Ozempic.

The Long-Term Question: Sustainability and Safety

A key concern surrounding GLP-1s is long-term sustainability. Research suggests that weight regain is common after discontinuing the medication, with participants in one study regaining two-thirds of lost weight within a year of stopping treatment. This raises questions about whether GLP-1s are a long-term solution or require indefinite use. As Ozempic was only approved by the FDA in 2017, there isn’t enough long-term research showing if extended use of this drug is safe.

Potential side effects also warrant careful consideration. Common side effects include nausea, vomiting, and diarrhea, while more serious risks, though rare, include possible thyroid tumors, pancreatitis, and kidney failure. Healthcare providers must carefully weigh the risks and benefits before prescribing these medications.

The Future Landscape: What’s on the Horizon?

The current GLP-1 landscape is rapidly evolving. Here’s what experts anticipate:

  • New Formulations and Delivery Methods: Beyond injectables, pharmaceutical companies are exploring oral GLP-1 formulations, potentially increasing accessibility and convenience.
  • Combination Therapies: Researchers are investigating combining GLP-1s with other medications or lifestyle interventions to enhance efficacy and address individual needs.
  • Personalized Medicine: Genetic testing and biomarker analysis may help identify individuals who are most likely to benefit from GLP-1 therapy and minimize potential side effects.
  • Increased FDA Scrutiny: As off-label use continues, the FDA is likely to increase scrutiny and potentially expand approvals for specific weight management applications.
  • Focus on Holistic Approaches: Experts emphasize that medications like Ozempic should be part of a comprehensive plan that includes dietary changes, increased physical activity, and stress management.

Nina Crowley, Ph.D., RD, emphasizes the importance of distinguishing between desiring weight loss and having the medical condition of obesity, as defined by a BMI over 30. This distinction is crucial for appropriate medical intervention.

Beyond Medication: The Role of Nutrition

Regardless of whether someone is taking a GLP-1 medication, prioritizing nutrient-dense foods is essential. Dietitians recommend incorporating fruits like avocados, cranberries, and kiwi into the diet, particularly for those on GLP-1s, to help manage potential side effects and ensure adequate nutrient intake. Focusing on anti-inflammatory foods and regular exercise are also key components of a healthy lifestyle.

FAQ

  • Is Ozempic safe for everyone? No. It’s crucial to discuss potential risks and benefits with a healthcare provider.
  • Will I regain weight if I stop taking Ozempic? Weight regain is common after discontinuing the medication.
  • Are there alternatives to Ozempic for weight loss? Yes, lifestyle changes, including diet and exercise, are fundamental.
  • Is BMI a reliable measure of health? BMI has limitations and doesn’t account for individual factors like body composition.

Pro Tip: Before considering any weight loss medication, consult with a registered dietitian to develop a personalized nutrition plan.

the future of weight management will likely involve a multifaceted approach, integrating pharmacological interventions with lifestyle modifications and personalized strategies. It’s a complex landscape, and informed decision-making, guided by healthcare professionals, is paramount.

Did you recognize? The weight loss industry is a multi-billion dollar market, but sustainable results often come from consistent lifestyle changes rather than quick fixes.

Seek to learn more about healthy eating habits? Explore more articles on AOL Lifestyle.

0 comments
0 FacebookTwitterPinterestEmail
Health

GLP-1 drugs linked to bone fracture risk in older diabetes patients, study finds

by Chief Editor
written by Chief Editor

The Shifting Landscape of GLP-1s: Bone Health and the Future of Weight Loss Drugs

GLP-1 medications like Ozempic and Wegovy have revolutionized the treatment of type 2 diabetes and obesity, but emerging research is prompting a closer look at potential side effects, particularly concerning bone health in older adults. A recent study published in the Journal of Clinical Endocrinology & Metabolism revealed an 11% higher risk of fragility fractures in those over 65 starting GLP-1s compared to those using other diabetes medications.

Why the Concern? A Deeper Dive into Bone Density

While the increased risk appears modest, experts emphasize its significance for a vulnerable population already predisposed to fractures. Both age and type 2 diabetes independently increase fracture risk, making this group particularly susceptible. The concern isn’t new, but is gaining traction as newer, more potent GLP-1s become widely prescribed.

Previous research with older GLP-1 medications didn’t show the same increased fracture risk. However, contemporary medications are different, and the patient demographic is changing.

Weight Loss and Bone Health: A Complex Relationship

The link between GLP-1s and bone health isn’t fully understood, but several factors are likely at play. Rapid weight loss, a common effect of these medications, is known to reduce bone density. This occurs because less mechanical load is placed on the skeleton. Sense of astronauts in zero gravity – without the constant stress of weight-bearing, bone density declines.

reduced calorie intake associated with weight loss can lead to lower consumption of essential nutrients like calcium, vitamin D, and protein, all crucial for maintaining bone strength. Separate research presented at the American Academy of Orthopaedic Surgeons’ annual meeting indicated a 29% higher relative risk of osteoporosis over five years in GLP-1 users compared to non-users, and slightly higher rates of gout.

Beyond Fractures: Osteoporosis and Gout on the Rise?

The emerging data suggests a potential connection between GLP-1 use and an increased risk of osteoporosis, and gout. One study found that gout affected 7.4% of GLP-1 users compared to 6.6% of non-users – a roughly 12% relative increase. Osteomalacia, a softening of the bones, was also observed at a higher rate in GLP-1 users, though this finding requires further investigation.

What Does This Mean for Patients and Physicians?

Experts are quick to emphasize that these findings shouldn’t discourage the appropriate use of GLP-1 medications. These drugs offer significant benefits for blood sugar control, weight loss, and cardiovascular risk reduction. However, a more proactive approach to monitoring bone health is warranted.

Proactive Steps for Bone Health

Before initiating GLP-1 therapy in older adults, healthcare providers should assess bone density. Alongside medication, patients should prioritize adequate nutrition, including sufficient calcium, vitamin D, and protein intake. Resistance training is also crucial for maintaining muscle mass and bone strength during weight loss.

Novo Nordisk, the manufacturer of Wegovy and Ozempic, acknowledges the importance of patient safety and continues to monitor research related to its products. The current FDA-approved labeling reflects known risks and benefits.

Future Trends and Research Directions

The conversation surrounding GLP-1s is evolving. Here’s what we can expect to observe in the coming years:

  • Personalized Medicine: Tailoring GLP-1 therapy based on individual risk factors, including bone health status.
  • Combination Therapies: Exploring the use of bone-strengthening medications alongside GLP-1s for high-risk patients.
  • Long-Term Studies: Conducting more extensive long-term studies to fully understand the impact of GLP-1s on bone health and other potential side effects.
  • New Formulations: Development of GLP-1 formulations designed to minimize potential negative effects on bone metabolism.

FAQ: GLP-1s and Bone Health

Q: Should I stop taking my GLP-1 medication if I’m concerned about my bone health?
A: No. Discuss your concerns with your doctor. They can assess your individual risk factors and determine the best course of action.

Q: What tests can be done to assess my bone health?
A: A bone density scan (DEXA scan) is the most common test used to measure bone density.

Q: Are there any lifestyle changes I can make to protect my bones while taking GLP-1s?
A: Yes. Ensure you’re getting enough calcium, vitamin D, and protein in your diet, and engage in regular weight-bearing exercise.

Q: Does this apply to all GLP-1 medications?
A: The research is ongoing, but current evidence suggests the risk may be higher with newer, more potent GLP-1s.

Did you realize? Resistance training, even simple exercises like lifting light weights or using resistance bands, can significantly improve bone density.

Stay informed about the latest developments in GLP-1 research and discuss any concerns you have with your healthcare provider. The future of weight loss medication is promising, but a cautious and informed approach is essential.

Explore more lifestyle stories on Fox News.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts